CDK4 and breast cancer: Moreover, Condorelli and colleagues showed, through a ct-DNA analysis, that loss of function of RB1 after CDK4/6 inhibitor treatment (palbociclib/ribociclib) was associated with acquired CDK4/6 inhibitor resistance in patients with metastatic BC [46].